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Purpose: To evaluate and compare the performance of 9 experimental DMBT tandem models of
varying physical dimensions in relation to 24 previously planned HDR cervical cancer treatment
plans from multiple institutions that used conventional tandem and rings or ovoid applicators..
Methods and Materials: The DMBT tandem is designed to be used concurrently with IGABT
and is made from an MRI-compatible tungsten-alloy rod with 6 channels grooved out of its
periphery. 9 experimental DMBT tandem prototypes were provided. Each of the models were of
equal lengths but varied in thickness, channel diameter size, and circle channel diameter size.
Replanning was performed using our research TPS (BrachyVisionÒ v.16.1, Varian, Palo Alto,
CA). Inverse optimization using Acuros was performed for 12 patient cases (24 plans) belonging
to three institutions: Virginia Commonwealth University, University of Michigan, and University
of California San Diego. Original plans used conventional tandem and ovoids or ring applicators.
Each of the 9 DMBT tandem models replaced the location of the original tandem such that the
new dwell positions were at the level of the original plan’s. The dwell positions of the ovoids or
rings remained unchanged.
Results: The average relative reduction in D2cc using the thinnest DMBT tandem (model 1)
were: -9.65% (∆EQD2 D2ccBladder = -3.6 Gy), -19.91% (∆EQD2 D2ccRectum = -3.87 Gy), and 14.55% (∆EQD2 D2ccSigmoid = -3.55 Gy), for the bladder, rectum, and sigmoid respectively. The
average relative reduction in D2cc using the thickest DMBT tandem (model 9) were: -12.82%
(∆EQD2 D2ccBladder = -4.05 Gy), -24.69% (∆EQD2 D2ccRectum = -4.05 Gy), and -18.42%
(∆EQD2 D2ccSigmoid = -3.63 Gy), for the bladder, rectum, and sigmoid respectively.
Conclusions: Significant reductions in OAR dose while maintaining identical target coverage
(D90) can be achieved by the use of any of the 9 DMBT tandem models. As DMBT tandem
thickness increases, OAR dose decreases; however, there are no significant difference in
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performance between models. Unless necessary to remain within an OAR’s total dose (EQD2)
limit, we advise the use of a moderately thick DMBT tandem (model 5) for clinical use as its
physical dimensions resemble that of already used clinically conventional tandems while
offering enhanced modulating capabilities.

KEYWORDS
Direction-modulated brachytherapy (DMBT), Image-guided adaptative brachytherapy (IGABT),
organ-at-risk (OAR)
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1. Introduction

1.1.

Birth of Brachytherapy

The turn of the twentieth century was characterized by immense scientific discoveries that would
affect the field of medicine and physics forever. One such discovery was that of radioactivity by
Henri Becquerel in 1896. Shortly after, notable scientists such as Pierre Curie and Alexander
Graham Bell suggested the use of this newly discovered property of radioactivity as a means of
treating cancer and other malignant diseases. It was believed that this could be accomplished by
implanting a radioisotope of radium into the body, near or around the site of the primary tumor.
This proposed technique was first implemented in 1901 at the St. Louis Hospital in Paris where a
patient suffering of lupus was treated using radium sulfate1. This treatment was amongst one of
the earliest accounts of the technique commonly known as brachytherapy and marked the birth of
the field of radiation therapy. In 1903, the first use of brachytherapy for the treatment of a
gynecological disease was documented. In New York, a patient with cervical cancer was treated
using 700 mg of radium bromide enclosed in glass tubing1. As the twentieth century progressed,
technological advances complimented the growing field of radiation therapy. In the early
century, X-ray machines were engineered to produce stronger and stronger energies. With the
advent of nuclear reactors during World War II, the creation and use of artificially produced
radionuclides such as cobalt 60 were incorporated for treatment purposes. By the 1970s the first
medical linear accelerator was created and was able to produce even greater energies which have
become a hallmark of modern day radiotherapy. However; despite these technological
advancements in external beam radiation therapy (EBRT), brachytherapy still has its place and
remains a standard of care for many cancers associated with the prostate, cervix, skin, lung, and
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eyes. Brachytherapy, unlike external beam therapy, does not require ionizing radiation to
traverse large depths of penetration in healthy tissue since the source is placed near or within the
target. In addition, the average energy of common HDR sources are much lower than those used
in external beam therapy resulting in steeper dose gradients. Low energy sources such as 192Ir
which emits photons with an average energy of approximately 380 keV are often used. The close
proximity of the source to the target combined with its low average energy results in a high
degrees of dose deposition in the target with minimal OAR and healthy tissue exposure.

1.2.

Prognosis for Cervical Cancer

Cervical cancer is amongst the deadliest gynecological malignancies for women and is the
leading cause of cancer mortality for women in developing countries 2. This can be in part due to
a lack of access to the human papillomavirus (HPV) vaccine as multiple strains of the virus can
play a prominent role in the development of cancer. Mortality rates in the U.S from cervical
cancer have decreased by 70% due to screening with the Pap test3. However, it still remains the
3rd most common gynecological malignancy in the U.S. Risk factors for developing cervical
cancer include: early intercourse, multiple sexual partners, many pregnancies, smoking,
immunosuppression, prenatal estrogen, and exposure to HPV 16 and/or 184. Prescreening
procedures such as the Pap test or Colposcopy may be used to identify the cancer early while
vaccines such as Cervarix and Guardasil may be used to prevent it. The FIGO staging system
determined by the International Federation of Gynecology Obstetrics allows physicians to define
the extent of the disease and assign the appropriate treatment5.
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1.3.

Historical Treatment of Cervical Cancer

As noted previously, brachytherapy has been used to treat cervical cancer since the beginning of
the twentieth century; however, the technique of treatment planning has changed drastically. Due
to the technological limitations of the 1930s, only 2D radiographic imaging could be used for
treatment planning. From 2D images, prescription systems such as the Manchester system could
be utilized. This system designated a point at which the prescription system should be delivered
known as “point A”. In 1938, the Manchester system defined the location of point A at 2 cm
laterally from the center of the uterine canal and 2 cm superior of the mucosa membrane of the
lateral fornix in the plane of the uterus. Often times the top edge of the ovoids were used as a
surrogate for the fornix. The significance of this point lies in its proximity to the ureters which
were believed to be the dose limiting structure in treatment planning. However, a major
limitation of this prescription system is that point A is defined the same in all cases and doesn’t
take patient specific anatomy into account. It also relies on 2D imaging which doesn’t account
for the 3D spatial extent of the target and locations of nearby organs at risk (OAR), namely the
bladder, rectum, and sigmoid colon. This lack of 3D information makes identifying the locations
of OAR unrealistic and can lead to an increase likelihood of developing complications from
treatment7-9. In conjunction with the point A prescription system, the famous Fletcher rules were
utilized which defined various loading parameters (i.e. ratio of dwell times in various dwell
positions based on the size of tandem and ovoids used) in order to produce the historic pearshape dose distribution that has been associated with successful clinical outcomes10-12. However;
one of the primary disadvantages of the Fletcher system is that it assumes that all tumors are of
the same size and shape. Therefore, it does not account for cases of irregularly shaped tumors or
ones that have extended to the pelvic side walls11-12. In modern times, external beam radiation
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therapy (EBRT) followed by brachytherapy (BT) with or without concurrent chemotherapy has
become the standard of care for the treatment of cervical cancer10. Despite the technological
advancements of EBRT, it alone is not capable of delivering prescription doses without
producing significant side effects such as inflammation, fibrosis, necrosis, and fistulas due to the
proximity of nearby OARs11. This due to the increased depth of penetration required for ionizing
radiation in EBRT to reach its target. In addition, the field size in much larger than in BT causing
larger areas of healthy tissue to be irradiated. In BT, the source is placed inside the body within
or near the target. In addition, the energy of the source is much lower than in EBRT. The
combination of a lower energy and the closer proximity of the source to the target allows for
high dose deposition within the tumor while providing a steep dose gradient that spares nearby
OAR and surrounding healthy tissue.

1.4.

Transition from 2D to 3D IGABT

With the advent of 3D imaging modalities such as CT and MRI, image-guided adaptive
brachytherapy (IGABT) has become the favorable treatment planning technique over the point A
prescription system. Multiple prospective and single institutional studies have shown that 3D
IGABT can produce better local tumor control and reduce morbidity13-15. From the patientspecific volumetric information, the spatial position of the nearby OARs in relation to the highrisk clinical target volume (HRCTV) may be contoured in the treatment planning system. The
Groupe Européen de Curiethérapie and Eurpoean Society for Radiotherapy and Oncology have
created definitions for the HRCTV which would accommodate the transition from 2D to 3D
IGABT. The HRCTV is defined to be at least the entirety of the cervix in addition to any other
palpable extensions of the disease16. However, it becomes difficult to adhere to this definition

15

through the use of tandem and ovoid or ring applicators where it is difficult to confine the dose
distribution in the anterior-posterior directions17. In order to circumvent this challenge,
interstitial needles are often used which are capable of producing more conformal dose
distribution by careful selection of their placement (dwell position) as well as the source’s dwell
times. The summation of the isotropic dose distribution created by interstitial needles in various
dwell positions is summed with that produced by the tandem and ovoids/ring to create an
anisotropic dose distribution. The use of needles are especially helpful in the case of locally
advanced cervical cancer (LACC) for providing sufficient target coverage to laterally extended
disease that is too far away from the dose emitted from common intracavitary applicators While
interstitial needles are a useful tool for creating more conformal dose distributions, they are
prone to many errors. Ideal needle placement can be difficult to accomplish due lack of
experience and training on the part of the physician. To account for this, intracavitary-interstitial
hybrid applicators may be used but they are still prone to positioning errors due to the flexing of
the needles in the vaginal tissue. For these reasons, the exploration of alternative solutions have
ensued.

1.5.

Direction-Modulated Brachytherapy (DMBT)

Common intracavitary applicators still utilize an isotropic dose distribution; however, the highrisk clinical target volume (HRCTV) is often irregular in shape thus causing healthy tissue and
OARs to receive unnecessary dose. In addition, if the disease extends superiorly into the uterus,
then it will be difficult for the dose from the ovoids or rings to reach it. This means that the
majority of the dose will come from the isotropic source in the tandem which has poor dose
modulation. As discussed previously, one such solution to creating more conformal dose
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distribution, is the use of interstitial needles; however, this technique is only applicable to larger
HRCTV volumes in excess of 30 cm3. For these reasons, there has been a growing interest into
the implementation of a new anisotropic source that would complement the use of 3D imaging to
create more conformal dose distributions18-20. This technique is known as direction-modulated
brachy therapy (DMBT). Current work is being conducted in order to explore the possibility of
utilizing an experimental tandem prototype that would be capable of producing an anisotropic
dose distribution in line with the DMBT concept.

2. Purpose

The aim of our research is to evaluate and compare the performance of 9 experimental DMBT
tandem models of varying physical dimensions in relation to 24 previously planned HDR
cervical cancer treatment plans that used conventional tandem and rings or ovoids. We seek to
identify the improvements in OAR doses, recto-vaginal (RV-RP) dose, the doses to the posteriorinferior border of symphysis (PIBS) reference points, and the equivalent total OAR doses
delivered in 2 Gy fractions achieved by different DMBT tandem models for varying target sizes.
We also seek to make recommendations for which model(s) should be used clinically.
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3. Methodology

3.1.

DMBT Tandem

The experimental DMBT tandem is designed with 6 channels bored out of the periphery of a
non-ferromagnetic tungsten-alloy rod (⍴ = 18.0 g/cm3) and can be seen in Figure 1. The
tungsten-alloy rod is composed of 95% tungsten, 3.5% nickel, and 1.5% copper21. The materials
composing the alloy were carefully selected to be MRI compatible, creating minimal
susceptibility artifact22. The density of tungsten is responsible for the modulation of the beam.
Because the source channels are located at the periphery of the rod, radiation emitted towards the
opposing side of the tandem will be attenuated with minimal transmission (16.5% for Ir-192 at 1
cm depth)23. In this study, 9 DMBT tandem models were evaluated and are shown in Figures 23. The models varied in regards to select physical dimensions (see Table 1 and Figure 4). Each
model followed an identical 6 channel construction with equal tandem lengths of 80 mm while
utilizing the same composition of tungsten-alloy material.
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Figure 1. (a) A conventional tandem and ovoid applicator. (b) The direction-modulated brachytherapy (DMBT)
tandem design with 6 peripheral holes born out of a non-ferromagnetic tungsten alloy. (c) A cross-section of a
conventional tandem. (d) A cross-section of the DMBT tandem.

19

Figure 2. DMBT tandem models 1-4. Note the increase in thickness with increasing model number.

Figure 3. DMBT tandem models 5-9. Note the increase in thickness with increasing model number.
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Table 1. The physical dimensions of all 9 DMBT tandem models in order of increasing tandem thickness and
channel thickness. All models are 80 cm long.

Figure 4 . Definitions of the physical dimensions of the DMBT tandem
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3.2.

Patient Cohort

A total 484 previously treated HDR cervical cancer treatment plans belonging to 96 patients was
provided by three institutions: Virginia Commonwealth University (VCU), University of
Michigan (UMich), and University of California San Diego (UCSD). The treatment plans
selected for our study were filtered on four criteria. First, only plans containing all necessary
import files were included. Second, plans that used intracavitary applicators only were selected.
Third, since our patient population contained an insufficient number of patients simulated with
MRI imaging, CT simulated only patients were selected. Lastly, only plans with straight or
nearly straight tandems were selected. This consideration was made so that the straight prototype
DMBT tandem could be aligned in the same position as the conventional tandem used by the
original plan. Applying these considerations left us with a cohort of 24 previously treated CT
based intracavitary plans (T&O and T&R) belonging to 12 patients. 4 patients with 14 total
plans, 3 patients with 5 total plans, and 5 patients with 5 total plans belonged to UCSD, UMich,
and VCU respectively. Of the original 24 plans, 8 plans used T&O and the remaining 17 used
T&R. HRCTV sizes range from 7.71 cm3 to 56.30 cm3 with an average of 21.88 cm3.
Prescription doses ranged from 5.5 Gy to 7.5 Gy. FIGO stages ranged from IB1 to IVB. The
number of fractions replanned with the DMBT tandem per patient ranged from 1 to 4. A
summarized table of the patient cohort can be seen in Table 2.
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Table 2 . Data on our 12 patient cohort used in our study. 17 plans belonged to 5 patients using T&R while the
remaining 8 plans belonged to 7 patients using T&O. The # of fractions replanned represents only the number of
fractions in which the DMBT tandem replaced the conventional tandem. For example, a patient may have had 4
fractions treated originally but we may have only have used the DMBT tandem in 2 of those fractions.

3.3.

Sources and Afterloaders

In this study, two remote afterloaders were used including Varian’s VariSource ix and
GammaMed plus ix devices which used the VS200 Ir-192 (see Figure 5) and GammaMed Plus
Ir-192 (GMP Ir-192) (see Figure 6) sources respectively. The treatment date for each plan was
set to the calibration date of both sources which was 9/10/2020. The activity and source strength
of the VS2000 Ir-192 model were 10 Ci and 40300 cGy•cm2/h respectively. The activity and
source strength of the GMP Ir-192 model were 10 Ci and 40700 cGy•cm2/h respectively. Of the
12 patients, 9 (from VCU and UCSD) and 3 (from Umich) were treated with Varian’s
VariSource ix and GammaMed afterloaders ix respectively.
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Figure 5. Materials and dimensions (mm) of the Varian Medical Systems VS2000 source42

Figure 6. Materials and dimensions (mm) of the Varian Medical Systems VS2000 source43
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3.4.

Treatment Planning

3.4.1. Applicator Alignment
All 24 intracavitary treatment plans were imported into our research treatment planning system
(BrachyVisionÒ v.16.1, Varian, Palo Alto, CA) which contained all 9 DMBT tandem models
(see Figure 7). Copies of the original plans were made for each of the 9 DMBT tandem models.
The digitized DMBT tandem models were added to the original plans and aligned in the same
position as the conventional tandem (see Figures 8-9). Once the DMBT tandem was successfully
aligned, each dwell position in the six channels were at the same level as the dwell positions of
the conventional tandem(see Figures 10-11). Dwell positions of the ovoids or rings remained
unchanged.

Figure 7 . Solid applicator menu containing all 9 DMBT tandem models in our research TPS’s BrachyVision®
software.
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Figure 8. Digitized DMBT tandem unaligned with the original plan’s conventional tandem.

Figure 9. Digitized DMBT tandem aligned with the original plan’s conventional tandem.
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Figure 10. The original dwell positions used by the conventional tandem.
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Figure 11. The new DMBT tandem’s dwell positions are set to be equivalent to the dwell positions used by the
original plan’s conventional tandem. Blue rectangles indicate the dwell positions of the conventional tandem. Pink
rectangles indicate the dwell positions of the DMBT tandem.

3.4.2. Reference Point Specification
Many cervical cancer survivors have incurred late-effects post treatment such as vaginal
morbidity which can lead to sexual dysfunction 24-27. The most abundant example is vaginal
stenosis in which the vagina develops fibrous tissue due to radiation damage resulting in
shortening of the vaginal canal 26,28. Increasing vaginal doses will increase the likelihood of
developing such late-effects. For this reason, we measured the dose to the vagina using a vaginal
dose reporting method which accounts for the contributions from both external beam
radiotherapy (EBRT) and brachytherapy (BT) 29. In this method, reference points are set along
the center of the vaginal canal in order to account for dose to the lower and middle portions of
the vagina. To do this, a straight line is drawn from the posterior border of the symphysis bone
(as identified on sagittal image slices) to the center of the tandem which acts as a surrogate for
the center of the vaginal canal. The intersection of these two points is referred to the as the
Posterior-Inferior Border of the Symphysis (PIBS) dose point. In order to set the PIBS reference
points, a sagittal slice was selected in which the inferior most portion of the pubic symphysis
bone was visible. The displayed view was rotated such that the horizontal dashed alignment lines
were parallel with the bottom of the pubic symphysis bone. The vertical dashed alignment lines
were then aligned along the center of the tandem which acted as a surrogate for the vaginal canal.
The PIBS point was set at this location (see Figure 12). Additional PIBS points are measured at 1
cm and 2 cm superior and inferior to the PIBS points. To set these points, the measurement tool
was used to measure 1 cm and 2 cm in the superior and inferior direction from the PIBS point
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along a straight vertical path from the center of the tandem (see Figures 13-16). In addition , we
sought to account for the dose to the upper vagina by measuring the dose to the ICRU’s rectovaginal reference point (RV-RP). According to the EMBRACE-1 study, a dose-effect
relationship was created which related dose to the RV-RP to the likelihood of developing vaginal
morbidity 29,30. The RV-RP is defined as a point measured from the level of the superior end of
the vaginal reference length (see Figure 17) to 5 mm laterally inwards of the rectum. The
displayed view was rotated such that the horizontal dashed alignment lines could would be
parallel with the junction of the tandem (the curve of the tandem) and passing through the
rectum. The measurement tool within the TPS was used to measure 5 mm into the rectum along
the dashed horizontal alignment line where the RV-RP was then set (see Figure 18).

Figure 12 . Setting the PIBS point using the dashed horizontal alignment lines parallel with inferior border of the
symphysis bone. The dashed vertical alignment lines were then set to the center of the tandem and were used as a
guide for setting the remaining PIBS points.
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Figure 13. Setting the PIBS+1 point by measuring 1 cm superior from the PIBS point using the measurement tool
and guided by the dashed vertical alignment line.

Figure 14. Setting the PIBS+2 point by measuring 1 cm superior from the PIBS+1 point using the measurement tool
and guided by the dashed vertical alignment line.
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Figure 15. Setting the PIBS-1 point by measuring -1 cm inferior from the PIBS point using the measurement tool
and guided by the dashed vertical alignment line.

Figure 16. Setting the PIBS-2 point by measuring -1 cm inferior from the PIBS-1 point using the measurement tool
and guided by the dashed vertical alignment line.
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Figure 17. Definitions of the vaginal dose reference points (PIBS) and the ICRU’s RV-RP
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Figure 18. Setting the RV-RP using the dashed horizontal alignment lines parallel with the junction of the tandem.
The measurement tool was then used to measure 5 mm into the rectum were the point was set.

3.4.3. Structure Generation
To ensure that the DMBT tandem’s 100% isodose line retained the same shape as the original
plan (pear-shape in the case of T&O plans), artificial contour structures were created. First, the
100% isodose line of the original plan was converted into a structure denoted as the “100% dose”
structure (see Figure 19). Next, the Contour application was used to create two optimization
structures. The first of which was the PTV which was created from subtracting areas of overlap
between the OARs and the 100% dose structure while overlapping with the HRCTV (see Figures
20-21). This artificial PTV structure was used to maintain the shape of the 100% isodose line
from the original plan. A second structure known as Optimization 2 (OPT2) was created to be a
3mm symmetric expansion about the PTV while excluding areas of overlap (see Figure 22).
Thus OPT2 could be thought of as an outer rind or shell about the PTV and was used in order to
confine the regions of high dose from extending into nearby OARs during the following
optimization step.
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Figure 19. The 100% isodose structure (cyan) is created from the 100% isodose line (green) of the original plan
and is used to subsequently contour the PTV and OPT2 structures.

Figure 20. Creating the PTV. The first step was to create a structure that was equivalent to the 100% dose structure
(cyan) excluding areas of overlap with the bladder (blue) , rectum (green), and sigmoid (magenta).
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Figure 21. Creating the PTV (pink). The second step was to take the PTV structure created in Figure 20. and include
areas missing the HRCTV (red). Note the extension of the PTV that now includes the HRCTV in the anterior
direction. The PTV structure was created to maintain the shape of the original plan’s 100% isodose line after
optimization using the DMBT tandem model.
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Figure 22. Creating the optimization 2 (OPT2) structure (white). A 3 mm symmetric outer margin was created from
the PTV while excluding areas of overlap with the PTV. This created a rind or shell about the PTV. The OPT2
structure was used to confine areas of high dose from passing into nearby surrounding OAR during the optimization
step.

3.4.4. Plan Optimization
Inverse optimization was performed using VEGO Acuros BV Volume Optimization in order to
optimize and calculate the anisotropic Ir-192 doe distributions (see Figure 23). From this
platform, the reporting medium was set to be equivalent to water. In this way, the tungsten-alloy
heterogeneity of the DMBT tandem could be accounted for while minimizing the optimization
time by treating all other heterogeneities including bone, soft tissue, and the ovoids or rings as
water. This not only allows the heterogeneity of the DMBT tandem to be taken into account, but
also provides a fair comparison to the original treatment plans which used TG-43 dose
computation which considers a completely homogeneous water environment. Lower limit OAR
dose constraints were represented by the D2cc and D1cc values of the original plan. Upper and
lower HRCTV constraints were created in order to maintain the D90 value to within ± 1% of the
original plan’s D90. The artificially produced PTV structure was set such that at least 90% of its
volume received at least 90% of the dose. This ensured that the new 100% isodose line would
resemble the shape of the original plan’s 100% isodose line. Lastly, the OPT2 constraint was set
to receive no more than 100% of the dose to no more than 1cm3 of its volume ensuring that
regions of high dose were prohibited from extending into the surrounding OAR (namely the
bladder). The allowable violation of any OAR constraint was permitted to range from 1-10%
while both the upper and lower limits on the HRCTV allowed no violation from the desired
constraints ensuring strict obedience to the original plan’s D90 value.
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Figure 23. The optimization and calculation step used VEGO Acuros BV Volume optimization. The original plan’s
D2cc and D1cc OAR values were inputted as lower limits. The HRCTV constraints included and upper and lower
constraint in order to ensure that the DMBT tandem plan’s D90 value was maintained to within ±1% of the original
plan’s D90. An upper limit on the PTV was set to ensure that at least 90% of the volume received 90% of the dose.
This ensured that the DMBT tandem plan’s 100% isodose line closely resembled that of the original plan’s. The
lower limit set on the OPT2 constraint of no more than 1cc receiving no more than 100% of the dose ensures that
regions of high dose are confined close to the DMBT tandem and to prevent hot spots in nearby OARs such as the
bladder.

3.4.5. Data Collection
Upon successful completion of the optimization process, values from the new plan’s DVH were
recorded including the OAR D2cc and D1cc values and the HRCTV’s D90 and V100 values. In
addition, the dose to the RV-RP and all PIBS reference points were noted. The values of the
original plan using the conventional tandem were then compared to the values of the new DMBT
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tandem plan. Relative and absolute reductions in OAR doses were documented as well as the
deviation in the new plan’s D90 and V100 values from those of the original plan. The resulting
plan was then compared to the original plan using the plan evaluation application in order to
ensure that the shape of the original plan’s 100% isodose line was retained.

3.5.

Total Dose Calculation

The total biologic effective dose (EQD2) OAR D2cc values accounting for the contributions
from external beam therapy and brachytherapy were calculated for all original and DMBT
tandem plans and compared to those recommendations set by a 2021 ABS34-39 review (see
Figure 24) using the Withers formula (see Figure 25). The EBRT total dose was assumed to
follow a common fractionation scheme of 45 Gy delivered over 25 fractions. The brachytherapy
fractionization scheme was determined from the patient information provided that included the
number of fractions and that the prescription dose per fraction . The modernly defined α/ β value
of 3 corresponding to the late-responding OARs were selected43.

Figure 24. Total biologic effective dose (EQD2) limits (EBRT+BT) recommendations for the HRCTV and OAR in
the treatment of cervical cancer from a recent 2021 ABS review article.
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Figure 25. The Withers formula used for calculating the total biologic effective dose (EQD2) to each OAR. “D”
represents the total dose received over all fractions, “d’ represents the dose per fraction, and the α/ β value was
selected as 3 in accordance with the modernly accepted value for late-responding tissues.

3.6.

Treatment Time Recording

Of additional concern was the amount of additional treatment time required with the use of the
DMBT tandem. Because the activity of the source used varied amongst the original plans
provided, we first had to scale the treatment times as if the 10 Ci source used by the DMBT
tandem was utilized. In this way, the total treatment times between the original plans and the
DMBT tandem plans could be compared fairly.

4. Results

4.1.

Average Relative & Absolute OAR Dose Reduction

The D2cc values for each plan averaging the results from each of the 9 DMBT tandem models is
presented in Table 3. The average relative reduction in the D2cc from using the DMBT tandem
models for all patients were -11.00%, -21.76%, and -15.84% for the bladder, rectum, and
sigmoid respectively. The maximum relative D2cc reductions achieved for a particular patient

39

from all DMBT tandem models was -16.28%, -52.13%, and -38.76% for the bladder, rectum,
and sigmoid respectively.

Table 3 . D2cc values of each plan averaging the results from each of the 9 DMBT tandem models compared to the
original plans.. Green shaded regions indicate areas of improvements over the original plan

The average relative reductions from each of the 9 DMBT tandem model averaged over all 24
plans are presented in Table 4 along with the average relative difference in D90 and V100 from
the original plan. Note that the DMBT tandem plan’s average D90 values varied no more than
±1% from the original plans indicating nearly identical HRCTV coverage. The average relative
D2cc reductions from model 1 (thinnest model) were -9.65%, -19.91%, and -14.55% for the
bladder, rectum, and sigmoid respectively. The average relative D2cc reductions from model 5
(moderate thickness) were -10.00%, -21.14%, and -15.61% for the bladder, rectum, and sigmoid
respectively. The average relative D2cc reductions from model 9 (thickest model) were -12.82%,
-24.69%, and -18.42% for the bladder, rectum, and sigmoid respectively. The difference in
average relative D2cc reduction between the thickest (model 9) and the thinnest (model 1)
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DMBT tandems models were 3.17%, 4.78 %, and 3.87 % for the bladder, rectum, and sigmoid
respectively. It is worth noting that the relative D2cc reduction for the smallest target (HRCTV =
7.71 cm3) averaging the results from all 9 DMBT tandem models were -13.65%, -52.13%, and 38.76% for the bladder, rectum, and sigmoid respectively. This corresponds to an absolute D2cc
reduction of -0.71 Gy, -1.74 Gy, and -1.41 Gy for the bladder, rectum, and sigmoid respectively
for the single fraction with a prescription dose of 7 Gy. The relative D2cc reduction for the
largest target (HRCTV = 56.3 cm3) averaging the results from all 9 DMBT tandem models were
-10.82%, -14.71%, and -17.28% for the bladder, rectum, and sigmoid respectively. This
corresponded to absolute D2cc reductions of -0.45 Gy, -0.45 Gy, and -0.51 Gy for the bladder,
rectum, and sigmoid respectively for a single fraction with a prescription dose of 6 Gy. The
maximum relative D2cc reduction for the bladder amongst all plans came from DMBT tandem
model 3 and was -18.17% which corresponded to an absolute D2cc reduction of -1.05 Gy for a
single fraction with a prescription dose of 7 Gy and a target volume of 15.74 cm3. The maximum
relative D2cc reduction for the rectum and sigmoid amongst all plans came from DMBT tandem
model 9 (thickest) and was -72.51% and -47.21% respectively which corresponded to absolute
D2cc reductions of -2.43 Gy and -1.72 Gy for a single fraction with a prescription dose of 7 Gy
and a target volume of 7.71 cm3 (smallest HRCTV).
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Table 4. The average relative variance in the D90 [%] and V100 [100%] as well as the average relative reduction in
the D2cc [%] and D1cc [%] of the bladder, rectum, and sigmoid for all 24 plans and for each of the 9 DMBT tandem
models.

Figures 26-27 show the average relative reduction in D2cc from the 1.1 mm and 1.3 mm channel
diameter DMBT tandem models respectively. Note the gradual improvement in relative D2cc
reduction with increasing DMBT tandem thickness (increasing model number).
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Figure 26. The average relative reduction in the D2cc of bladder, rectum, sigmoid for all 24 plans and for each of the
1.1mm channel diameter DMBT tandem models. Refer to fig. for DMBT tandem model details.

Figure 27. The average relative reduction in the D2cc of bladder, rectum, sigmoid for all 24 plans and for each of the
1.3mm channel diameter DMBT tandem models. Refer to fig. for DMBT tandem model details.
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4.2.

Target Size vs. Average Relative OAR Dose Reduction

The average relative D2cc reduction (%) for all plans is compared to HRCTV size (cm3) for
model 1 (thinnest), for model 5 (moderate thickness), and for model 9 (thickest) in Figure 28,
Figure 29, and Figure 30 respectively.

Figure 28. The relationship between HRCTV size (cc) and the average relative reduction in the D2cc of the bladder,
rectum, and sigmoid for the thinnest DMBT tandem model (model 1).
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Figure 29. The relationship between HRCTV size (cc) and the average relative reduction in the D2cc of the bladder,
rectum, and sigmoid for a moderate thickness DMBT tandem model (model 5).

Figure 30. The relationship between HRCTV size (cc) and the average relative reduction in the D2cc of the bladder,
rectum, and sigmoid for the thickest DMBT tandem model (model 9).

Figures 31-35 show the spatial dose distribution for various plans. Note the areas of improved
OAR dose sparing.
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Figure 31. The spatial dose distribution of the original plan (left) and the DMBT tandem plan (right). The red arrows
indicate areas of improved OAR sparing. This fraction belonged to patient 7 which had a HRCTV of 18.64 cm3 with
a prescription dose of 6 Gy. The absolute reduction in OAR D2cc values from this model were -0.92 Gy, -0.63 Gy,
and -0.42 Gy for the bladder, rectum and sigmoid respectively. Note the removal of the overlapping region of the
100% isodose line with the bladder when the DMBT tandem is used. Also note the retention of the pear-shape dose
distributions with the DMBT tandem while generating significant improvements.
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Figure 32. The spatial dose distribution of the original plan (left) and the DMBT tandem plan (right). The red arrows
indicate areas of improved OAR sparing. This fraction belonged to patient 1 which had a HRCTV of 9.84 cm3 with
a prescription dose of 7 Gy. The absolute reduction in OAR D2cc values from this model were -0.93 Gy, -0.96 Gy,
and -0.47 Gy for the bladder, rectum and sigmoid respectively. Note the removal of the overlapping region of the
100% isodose line with the sigmoid when the DMBT tandem is used.
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Figure 33. The spatial dose distribution of the original plan (left) and the DMBT tandem plan (right). The red arrows
indicate areas of improved OAR sparing. This fraction belonged to patient 8 which had a HRCTV of 56.30 cm3 with
a prescription dose of 6 Gy. The absolute reduction in OAR D2cc values from this model were -0.49 Gy, -0.46 Gy,
and -0.49 Gy for the bladder, rectum and sigmoid respectively.
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Figure 34. The spatial dose distribution of the original plan (left) and the DMBT tandem plan (right). The red arrows
indicate areas of improved OAR sparing. This fraction belonged to patient 2 which had a HRCTV of 13.77 cm3 with
a prescription dose of 7 Gy. The absolute reduction in OAR D2cc values from this model were -0.63 Gy, -0.55 Gy,
and -0.62 Gy for the bladder, rectum and sigmoid respectively. Note the removal of the overlapping region of the
100% isodose line with the bladder when the DMBT tandem is used. Also note the retention of the pear-shape dose
distribution with the DMBT tandem while generating significant improvements.

Figure 35. The spatial dose distribution of the original plan (left) and the DMBT tandem plan (right). The red arrows
indicate areas of improved OAR sparing. This fraction belonged to patient 2 which had a HRCTV of 13.06 cm3 with
a prescription dose of 7 Gy. The absolute reduction in OAR D2cc values from this model were -0.76 Gy, -0.69 Gy,
and -0.39 Gy for the bladder, rectum and sigmoid respectively. Note the removal of the overlapping region of the
100% isodose line with the bladder when the DMBT tandem is used. Also note that model 1 is the weakest
performing model and that significant improvements are made while maintaining the pear-shape dose distribution.
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4.3.

Total OAR Dose (EQD2) Reduction

The EQD2 D2cc values for each OAR and for each plan averaging the results of all 9 DMBT
tandem models are presented in Table 5. The absolute EQD2 D2cc reductions averaged over all
plans for all DMBT tandem model were -5.74 Gy, -4.02 Gy, -3.62 Gy for the bladder, rectum,
and sigmoid respectively. The average absolute EQD2 D2cc reduction for model 1 (thinnest)
were -3.60 Gy, -3.87 Gy, and -3.55 Gy for the bladder, rectum, and sigmoid respectively (see
Figure 36). The average absolute EQD2 D2cc reduction for model 5 (moderate thickness) were 4.18 Gy, -4.18 Gy, and -3.74 Gy for the bladder, rectum, and sigmoid respectively (see Figure
37) . The average absolute EQD2 D2cc reduction for model 9 (thickest) were -4.05 Gy, -4.05
Gy, and -3.63 Gy for the bladder, rectum, and sigmoid respectively (see Figure 38). The
difference in EQD2 D2cc reduction between the thickest (model 9) and the thinnest (model 1)
DMBT tandems models were 0.45 Gy, 0.18 Gy, and 0.08 Gy for the bladder, rectum, and
sigmoid respectively. 13 of the 24 original plans had at least one OAR failing its EQD2 D2cc
dose limits. For 12 of those 13 plans, the addition of at least one of the 9 DMBT tandem models
was able to lower the EQD2 D2cc for at least one OAR under its dose limit. Two notable plans
that were reduced below their EQD2 D2cc limits are shown in Tables 7-8.
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Table 5. Individual EQD2 D2cc values, averaged over each patient’s replanned fractions and all DMBT tandem
models compared to the conventional (T&O and T&R) plans.

Table 6. The average relative variance in the D90 [%] and V100 [100%] as well as the average absolute reduction in
the EQD2 D2cc [Gy] and EQD2 D1cc [Gy] of the bladder, rectum, and sigmoid for all 24 plans and for each of the 9
DMBT tandem models.
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Figure 36. The average absolute reductions in EQD2 D2cc [Gy] averaged over all 24 plans for the bladder, rectum,
and sigmoid for the thinnest DMBT tandem model (model 1). The top, middle, and bottom errors bars represent Q1,
median, and Q3 respectively. The top and bottom whisker represents the minimum and maximum ∆EQD2 D2cc
excluding outliers respectively. The “X” represents the average and the dots represent outliers.

Figure 37. The average absolute reductions in EQD2 D2cc [Gy] averaged over all 24 plans for the bladder, rectum,
and sigmoid for a moderately thick DMBT tandem model (model 5,). The top, middle, and bottom errors bars
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represent Q1, median, and Q3 respectively. The top and bottom whisker represents the minimum and maximum
∆EQD2 D2cc excluding outliers respectively. The “X” represents the average and the dots represent outliers.

Figure 38. The average absolute reductions in EQD2 D2cc [Gy] averaged over all 24 plans for the bladder, rectum,
and sigmoid for the thickest DMBT tandem model (model 9). The top, middle, and bottom errors bars represent Q1,
median, and Q3 respectively. The top and bottom whisker represents the minimum and maximum ∆EQD2 D2cc
excluding outliers respectively. The “X” represents the average and the dots represent outliers.
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Table 7. The absolute difference in total dose (EQD2) between a single plan from patient 7 and the DMBT plans.
Note the significant reduction in EQD2 D2cc for the bladder which was originally exceeding its total dose (EQD2)
limit of 80 Gy (red shaded region) using all DMBT tandem models (green shaded region).

Table 8. The absolute difference in total dose (EQD2) between a single plan from patient 5 and the DMBT plans.
Note the significant reduction in EQD2 D2cc for the bladder and rectum which were originally exceeding its total
dose (EQD2) limits (red shaded region) of 80 Gy and 65 Gy respectively using all DMBT tandem models (green
shaded region).

4.4.

Average Relative RV-RP & PIBS Dose Reductions

The average relative reduction by all 9 DMBT tandem models was -21.87%, -27.90%, -21.19%,
-17.97%, and -17.35% for the RV-RP, PIBS+2, PIBS+1, PIBS, PIBS-1, and PIBS-2 respectively
(see Table 9). The minimum relative reductions came from model 1 (thinnest) and were 19.30%, -21.55%, -16.30%, -13.99%, -14.50%, and -13.73% for the RV-RP point, PIBS+2,
PIBS+1, PIBS, PIBS-1, and PIBS-2 respectively. The maximum relative reductions came from
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model 9 (thickest) and were -26.49%, -37.84%, -29.99%, -25.75%, -22.45%, and -21.74% for the
RV-RP, PIBS+2, PIBS+1, PIBS, PIBS-1, and PIBS-2 respectively.

Table 9. The average relative reduction in the dose to the RV-RP (%) and PIBS points (%) for all 24 plans and for
each of the 9 DMBT tandem models.

4.5.

Treatment Time

The average increase in the total treatment time relative to the original treatment plan times are
shown in Table 10. Note that the total treatment time increases with increasing model
number/DMBT tandem thickness. The average total treatment time of all 24 original plans was
307.85 s (5.13 min.). The minimum and maximum average total treatment times produced by the
DMBT tandems were 324.19 s (5.4 min.) and 394.48 s (6.57 min.) respectively.
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Table 10. The average treatment time of all original plans and all DMBT tandem plans for each of the 9 models as
well as the average increase in the total treatment time
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5. Discussion

The results in Table 4 represent a general improvement of using all DMBT tandem models. One
may note that the smallest and greatest reduction in OAR dose with the aid of all DMBT tandem
models were to the bladder and rectum respectively. This may be explained by the close
proximity of the bladder to the tandem relative to the distant rectum. It is apparent that the
thickest DMBT tandem (model 9) reduced OAR doses to the bladder, rectum, and sigmoid by
the greatest amount relative to the other models. This is likely due to the increase thickness of the
tungsten-alloy which is used to attenuate backside radiation. On the contrary, the smallest
reduction in OAR doses to the bladder, rectum, and sigmoid came from the thinnest DMBT
tandem (model 1) and can likely be explained by the same principle. In general, as the DMBT
tandem thickness increases so does the relative reduction in OAR doses (see Figures 26-27).
Despite a 4 mm difference in thickness between the thickest (model 9) and thinnest (model 1)
DMBT tandem models, the difference in OAR dose reductions were minimal. It would appear
that only marginal improvements are achieved by the thicker DMBT tandem models; however,
these small differences may be considerable when straddling total dose (EQD2) limits for a
particular OAR. From the results, it may seem apparent that the thickest DMBT tandem (model
9) should be used; however, due to the small diameter of the cervical os, it becomes increasingly
difficult for correct applicator placement by the physician as the tandem thickness increases.
Model 5 was identified to be a potentially useful applicator in the clinical setting as its thickness
(5.4 mm) closely resembles that of conventional tandem used currently (3-6 mm). In addition,
the difference in OAR dose reductions between the moderately thick (model 5) and thickest
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(model 9) DMBT tandem models were marginal. This small deficit in performance for a
moderately thick (model 5) DMBT tandem may be a reasonable clinical compromise for better
ease and accuracy of placement. An additional consideration was the target size. It was observed
that the reduction in dose to the OAR decreased as HRCTV size increased. This was to be
expected as dose modulation decreases with increasing distance from the tandem (especially
beyond 2-3 cm from the DMBT tandem) due to the inverse square law. In addition, larger targets
may be closer to OARs and thus it becomes increasingly difficult to maintain sufficient target
coverage without depositing additional dose in those structures. Despite this, all plans regardless
of target size experienced significant reductions in OAR dose. Improvements were seen from our
plan with smallest (HRCTV = 7.71cm3) through the largest target (HRCTV = 56.3 cm3) plan. In
no plan for any DMBT tandem model did the new OAR dose values exceed the original plan’s
values. There was always improvement. The largest improvements in OAR dose reduction for
the sigmoid and rectum came from the smallest target (HRCTV = 7.71cm3). The largest relative
improvement in OAR dose to the bladder came from a plan with another small target (HRCTV =
15.74 cm3). This agrees with our expectation since the dose modulating capabilities of the
DMBT tandem are the strongest for small targets within 2-3 cm from the tandem. The spatial
dose distribution was also more conformal to the target as seen in Figures 31-35. In many cases
the visual improvement in the 100% isodose line for the bladder and sigmoid was apparent. The
new dose 100% isodose line retained a similar shape as the original while omitting areas of
overlap with OAR. In addition, the original plan’s pear-shape dose distribution which has been
associated with positive clinical outcomes was retained while using all DMBT tandem models.
Results representing the total dose (EQD2) reductions by all 9 DMBT tandem models are
presented in Table 6. It is shown that significant reductions in total dose (EQD2) was achievable
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for all OARs using any DMBT tandem model. As we expected the largest and smallest total dose
(EQD2) reductions came from the thicker (models 8 & 9) and thinner (models 1 & 2) DMBT
tandem models respectively. The DMBT tandem proved that it could successfully lower the total
dose of previously failing OAR to below their total dose limits. Significant results such as those
presented in Tables 7-8 suggest that the model of DMBT tandem isn’t necessarily important
when it comes to lowering the EQD2 as all model demonstrated similar results. Therefore, more
care can be taken into selecting the correct sized tandem based on the patient’s anatomy.
However; the slight increase in modulation from a thicker DMBT tandem may be necessary
when the predicted total dose (EQD2) borders its recommended limit. Significant reductions in
the recto-vaginal and vaginal dose reference points were achieved by all models. The greatest
improvements came from the thicker (models 8 & 9) DMBT tandem models while the smallest
improvements came from the thinnest (model 1) DMBT tandem model. These significant
reductions are likely to decrease the probability of developing vaginal morbidity for surviving
cervical cancer patients. Lastly, comparisons of the total treatment times between the original
and DMBT tandem plans were of concern. One limitation of DMBT tandem is the additional
treatment time dedicated to transferring the source between each of the six channels. In addition,
it was noted that as the DMBT tandem thickness increases so to did the total treatment time. This
is to be expected as increases in thickness imply more attenuating material which minimizes
transmission through the backside and periphery of the source channels. This requires longer
dwell times to create a given dose distribution. The thinnest (model 1) DMBT tandem was able
to produce comparable treatment times to the original plan while the maximum average increase
came from the thickest (model 9) with an additional time of roughly a minute and a half. While
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this increase in modulation comes with a price in regards to time, the average total treatment
time with each DMBT tandem model were clinically permissible.

6. Future Recommendations and Limitations

While our study examined a large variety of target sizes for simple intracavitary cases, it does
not include all brachytherapy treatment techniques. As discussed previously, the use of
interstitial needles results in increased invasiveness and is not ideal as their placement can be
difficult due to a lack of adequate physician training as well as flexing of the needles in the
vaginal tissue. In addition, symptoms such as swelling are associated with the use of needles. For
these reasons, we recommend that intracavitary-interstitial cases be examined using the DMBT
tandem in order to identify the extent to which the modulating capabilities of the tandem can
replace the need for some or all needles. In addition, the DMBT tandem prototype in this study
was designed to be straight while the uterine canal is curving. This makes the placement of the
current dMBT tandem design infeasible without potentially perforating uterine tissue . This
design was likely adopted for simplicity but in order for it to be a clinically viable option, a
curving DMBT tandem must be designed and constructed.

7. Conclusion

24 cervical cancer treatment plans previously treated by brachytherapy using conventional
tandems and rings or ovoids were replanned using each of the 9 DMBT tandem models. All
DMBT tandem models exhibited the ability to significantly lower OAR doses compared to
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conventional tandem plans while maintaining equivalent target coverage. As we expected, the
thicker DMBT tandem models performed better in this sense than the thinner models by virtue of
its slightly thicker tungsten-alloy material. There were no significant differences in performance
between all DMBT tandem models suggesting that the selection of a moderate thickness tandem
may be recommended for clinical use due to its ease of placement and adequate dose modulating
capabilities. In addition, OARs that previously exceeded their total (EQD2) dose limits when the
conventional tandem was used were lowered significantly below their limits when any of the
DMBT tandem models were used. Plans with both small and large targets benefited from the use
of the DMBT tandem. This has sparked interest into the extent of the tandem’s performance for
very large targets as the DMBT tandem could potentially eliminate the need for interstitial
needles in such cases.
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